Drug Trial Radar · NCT05819658
GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)
Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Jun 14, 2023
Primary completion
Oct 11, 2024
Study completion Oct 11, 2024
Sponsor
- Lead sponsor
- GemVax & KaelIndustry
- Sponsor type
- Industry
- First posted
- Apr 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 41 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will be conducted by the Sponsor to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered subcutaneously as a treatment for Progressive Supranuclear Palsy, (PSP). In 75 patients diagnosed with PSPR Richardson(PSP-RS) or PSP-Parkinsonism (PSP-P) at five hospitals in Korea, subcutaneous administration of GV1001 0.56 or 1.12 mg/day will be conducted with multicenter, randomized, double-blind, placebo-controlled, parallel design, prospective phase 2a.
Conditions
- Progressive Supranuclear Palsy
Interventions
GV1001 PlaceboDrug
0.9% normal saline
GV1001 0.56mgDrug
Lyophilized peptide from hTERT
GV1001 1.12mgDrug
Lyophilized peptide from hTERT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From the Baseline in the Total Score of PSP-rating ScaleTime frame: 24 weeks(6 months)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Kyung Hee University Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul Metropolitan Government Seoul National University Boramae Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.